Early and mature endothelial progenitors and VEGFR2+-cells in multiple myeloma: Association with disease characteristics and variation in different cell compartments

Leukemia Research

Volumn 35, Issue 9, 2011, Pages 1265-1268

  Udi, Josefina ^a   Wider, Dagmar ^a   Kleber, Martina ^a   Ihorst, Gabriele ^a   Müller, Antonia ^b   Wäsch, Ralph ^a   Engelhardt, Monika ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Endothelial cells (ECs); Endothelial progenitor cells (EPCs); Healthy controls; Monoclonal gammopathy of undetermined significance (MGUS); Multiple myeloma (MM)

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; CD34 ANTIGEN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BLOOD; CELL INFILTRATION; CELL MATURATION; CONTROLLED STUDY; DISEASE ACTIVITY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; REMISSION; STAGING; STEM CELL TRANSPLANTATION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELL COMPARTMENTATION; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80051471568     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.021     Document Type: Article

References (13)

1. Zhang H., Vakil V., Braunstein M., Smith E.L., Maroney J., Chen L., et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005, 105:3286-3294.
2. Ribas C., Colleoni G.W., Silva M.R., Carregoza M.J., Bordin J.O. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. Eur J Haematol 2004, 73:311-317.
3. Niemoller K., Jakob C., Heider U., Zavrski I., Eucker J., Kaufmann O., et al. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 2003, 129:234-238.
4. Negaard H.F., Iversen N., Bowitz-Lothe I.M., Sandset P.M., Steinsvik B., Ostenstad B., et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 2009, 23:162-169.
5. Vroling L., Lind J.S., de Haas R.R., Verheul H.M., van Hinsbergh V.W., Broxterman H.J., et al. CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br J Cancer 2010, 102:268-275.
6. Dome B., Dobos J., Tovari J., Paku S., Kovacs G., Ostoros G., et al. Circulating bone marrow-derived endothelial progenitor cells: characterization, mobilization, and therapeutic considerations in malignant disease. Cytometry A 2008, 73:186-193.
7. Rigolin G.M., Fraulini C., Ciccone M., Mauro E., Bugli A.M., De Angeli C., et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 2006, 107:2531-2535.
8. Kleber M., Ihorst G., Deschler B., Jakob C., Liebisch P., Koch B., et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol 2009, 83:519-527.
9. Westerweel P.E., Hoefer I.E., Blankestijn P.J., de Bree P., Groeneveld D., van Oostrom O., et al. End-stage renal disease causes an imbalance between endothelial and smooth muscle progenitor cells. Am J Physiol Renal Physiol 2007, 292:F1132-F1140.
10. Shaked Y., Henke E., Roodhart J.M., Mancuso P., Langenberg M.H., Colleoni M., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14:263-273.
11. Roodhart J.M., Langenberg M.H., Vermaat J.S., Lolkema M.P., Baars A., Giles R.H., et al. Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia 2010, 12:87-94.
12. Purhonen S., Palm J., Rossi D., Kaskenpaa N., Rajantie I., Yla-Herttuala S., et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A 2008, 105:6620-6625.
13. Case J., Mead L.E., Bessler W.K., Prater D., White H.A., Saadatzadeh M.R., et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007, 35:1109-1118.